Tecniplast and Charles River have announced a co-marketing agreement in Europe and Asia to promote complementary technologies that improve the microbiological environmental monitoring of individually ventilated cages (IVCs.) Tecniplast’s system, called Interceptor (patent pending), collects dust particles moving from cages to the exhaust filtration area, capturing them on a media that is ready for microbiological screening.
Charles River, a global leader in environment health monitoring, provides an optimized solution to screen the dust particles collected from the Interceptor.
“Through this co-marketing partnership, we will deliver to the Lab Animal Industry a scientifically preferable solution that meets both operational and regulatory requirements”, remarked Pietro Bernardini, Managing Director of Tecniplast.
The Interceptor from Tecniplast
Tecniplast, following the growing market demand for Environmental Microbiological Monitoring Systems, introduced Interceptor, a new frontier to monitor the hygienic state of laboratory animals with a highly sensitive solution for the collection of exhaust dust particles. In addition, the removal of biological samples from the IVC occurs in a contamination-free manner enabling the safe transfer of the sample from the microbiological unit under investigation to the laboratory. The product is simple, inexpensive, efficient and validated on Mouse Norovirus (MNV), a microbiological agent difficult to detect in the environment. Made of two parts - a stainless steel frame purposely designed to allocate a second piece of equipment plus an irradiated cardboard folder containing a sliding filter - Interceptor (patent pending) is the Tecniplast answer to the need of animal free microbiological monitoring. Interceptor is also retrofitable and meets European Union and Asian regulatory requirements.
Consumers will benefit from this new technology, which offers the following advantages:
The Interceptor is the result of four years of studies to find a reliable and efficient microbiological screening method; it complements Tecniplast’s significant product and service portfolio, which is positioned to deliver efficiency advantages to a wide array of industries while benefiting the welfare of animals.
Preliminary scientific results were presented at FELASA 2013 (Barcelona) and AALAS 2014 (St Antonio - USA). Two manuscripts have been submitted for review and recent results have been presented at FELASA 2016 (Brussels) and AALAS 2016 (Charlotte).
EAD® (Exhaust Air Dust) Testing from Charles River (Patent Pending)
The standard practice for monitoring the health of animals housed in IVCs is to employ the soiled bedding sentinel method. Sentinel animals refer to externally sourced animals that are introduced into a population, exposed to the resident animals or soiled bedding from the population and sampled in lieu of the principal animals. However, the major drawback to this method it is that it relies on indirect exposure for infectious agent detection. While the soiled-bedding method is still a standard practice, it should be noted that it is difficult to transmit several currently prevalent agents to sentinel animals via this method.
EAD® is an alternative method of screening environmental samples via PCR that enables you to overcome the known limitations of soiled-bedding sentinel health monitoring (patent pending). Charles River has qualified the combination of PCR testing and EAD® sampling as a scientifically feasible health monitoring alternative to soiled bedding sentinel testing. Our testing platform is compatible with the media which collects the dust particles from Tecniplast’s Interceptor. Furthermore, our experts are ready to work with animal facilities and Tecniplast specialists to determine how best to develop customized EAD®-based health monitoring programs to suit all requirements.
The new co-marketing partnership is expected to spark innovation by maximizing the product development talents and resources at both companies, while driving scale and efficiency in the partners' respective supply chains. The partnership is a strong strategic fit, leveraging the two leading companies’ respective strengths.
Tecniplast is the world leading company in the Lab Animal Industry in designing, manufacturing and distributing patented equipment for laboratory animals since 1949. Tecniplast has the most complete product portfolio of the industry, ranging from IVC systems, Laminar Flow, Bio containment IVC systems, Rack and Cage washers, Bedding handling systems, Bedding Disposal systems, Aquatics, Analysis systems, IVC monitoring and RFID census solutions to Decontamination Automation systems and a complete range of Accessories. Tecniplast has recently introduced on the market the first Digital Ventilated Cage (DVCTM), defining new boundaries in the culture of care for daily management of lab animal facilities.
We continuously invest with the objective to provide you the most reliable and relevant products range. Our constant investment in tooling, technologies, automation, production capability, stock availability, staff recruitment and training together with the ISO certified quality (ISO 9000) and environmental (ISO 14001) management systems certifications, offers the most dynamic innovation in the market, the most complete range of products with the highest level of quality.
We offer comprehensive solutions and services in Product Design, Ergonomic Planning, Environmental Responsibility, Space Planning, LEAN Audit and Budgetary Evolution. We assist clients in installation, training and service with a direct presence in ITALY, USA, France, UK, Germany, Australia, Japan and China and with a network of 67 International representatives in the rest of the world.
For more information on Tecniplast, visit: www.tecniplast.it
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com .